BACKGROUND: Recently, we reported a novel oligoguanidine transporter system, polyarginine (R(7)), which, when conjugated to spectroscopic probes (e.g., fluorescein) and drugs (e.g., cyclosporin A), results in highly water-soluble conjugates that rapidly enter cells and tissues. We report herein the preparation of the first R(7) peptide conjugates and a study of their cellular and organ uptake and functional activity. The octapeptide (psi)(epsilon)RACK was selected for this study as it is known to exhibit selective epsilon protein kinase C isozyme agonist activity and to reduce ischemia-induced damage in cardiomyocytes. However, (psi)(epsilon)RACK is not cell-permeable. RESULTS: Here we show that an R(7)-(psi)(epsilon)RACK conjugate readily enters cardiomyocytes, significantly outperforming (psi)(epsilon)RACK conjugates of the transporters derived from HIV Tat and from Antennapedia. Moreover, R(7)-(psi)(epsilon)RACK conjugate reduced ischemic damage when delivered into intact hearts either prior to or after the ischemic insult. CONCLUSIONS: Our data suggest that R(7) converts a peptide lead into a potential therapeutic agent for the ischemic heart.
BACKGROUND: Recently, we reported a novel oligoguanidine transporter system, polyarginine (R(7)), which, when conjugated to spectroscopic probes (e.g., fluorescein) and drugs (e.g., cyclosporin A), results in highly water-soluble conjugates that rapidly enter cells and tissues. We report herein the preparation of the first R(7) peptide conjugates and a study of their cellular and organ uptake and functional activity. The octapeptide (psi)(epsilon)RACK was selected for this study as it is known to exhibit selective epsilon protein kinase C isozyme agonist activity and to reduce ischemia-induced damage in cardiomyocytes. However, (psi)(epsilon)RACK is not cell-permeable. RESULTS: Here we show that an R(7)-(psi)(epsilon)RACK conjugate readily enters cardiomyocytes, significantly outperforming (psi)(epsilon)RACK conjugates of the transporters derived from HIV Tat and from Antennapedia. Moreover, R(7)-(psi)(epsilon)RACK conjugate reduced ischemic damage when delivered into intact hearts either prior to or after the ischemic insult. CONCLUSIONS: Our data suggest that R(7) converts a peptide lead into a potential therapeutic agent for the ischemic heart.
Authors: Michael B Ellman; Jae-Sung Kim; Howard S An; Jeffrey S Kroin; Xin Li; Di Chen; Dongyao Yan; Doug D Buechter; Keiichi Nakayama; Bo Liu; Stephanie Morgan; Hee-Jeong Im Journal: Arthritis Rheum Date: 2011-12-12
Authors: Paul A Wender; Wesley C Galliher; Elena A Goun; Lisa R Jones; Thomas H Pillow Journal: Adv Drug Deliv Rev Date: 2007-11-09 Impact factor: 15.470
Authors: Paul A Wender; Elena A Goun; Lisa R Jones; Thomas H Pillow; Jonathan B Rothbard; Rajesh Shinde; Christopher H Contag Journal: Proc Natl Acad Sci U S A Date: 2007-06-11 Impact factor: 11.205
Authors: R Anthony DeFazio; Ami P Raval; Hung W Lin; Kunjan R Dave; David Della-Morte; Miguel A Perez-Pinzon Journal: J Cereb Blood Flow Metab Date: 2008-10-29 Impact factor: 6.200